Tags

Type your tag names separated by a space and hit enter

New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Vaccine. 2021 01 08; 39(2):197-201.V

Abstract

The threat of the current coronavirus disease pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is accelerating the development of potential vaccines. Candidate vaccines have been generated using existing technologies that have been applied for developing vaccines against other infectious diseases. Two new types of platforms, mRNA- and viral vector-based vaccines, have been gaining attention owing to the rapid advancement in their methodologies. In clinical trials, setting appropriate immunological endpoints plays a key role in evaluating the efficacy and safety of candidate vaccines. Updated information about immunological features from individuals who have or have not been exposed to SARS-CoV-2 continues to guide effective vaccine development strategies. This review highlights key strategies for generating candidate SARS-CoV-2 vaccines and considerations for vaccine development and clinical trials.

Links

PMC Free PDF

Authors+Show Affiliations

Ura T
Department of Ophthalmology and Visual Science, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.
Yamashita A
Department of Molecular Biology, Graduate School of Medicine, Yokohama 236-0004, Japan.
Mizuki N
Department of Ophthalmology and Visual Science, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.
Okuda K
Department of Molecular Biodefense Research, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.
Shimada M
Department of Molecular Biodefense Research, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan. Electronic address: mshimada@yokohama-cu.ac.jp.

MeSH

Antibodies, ViralCOVID-19COVID-19 VaccinesClinical Trials as TopicGenetic VectorsHumansImmunity, InnateImmunization ScheduleImmunogenicity, VaccinePandemicsPatient SafetySARS-CoV-2Severe Acute Respiratory SyndromeVaccines, AttenuatedVaccines, DNAVaccines, SubunitVaccines, Virus-Like Particle

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

33279318

Citation

Ura, Takehiro, et al. "New Vaccine Production Platforms Used in Developing SARS-CoV-2 Vaccine Candidates." Vaccine, vol. 39, no. 2, 2021, pp. 197-201.
Ura T, Yamashita A, Mizuki N, et al. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine. 2021;39(2):197-201.
Ura, T., Yamashita, A., Mizuki, N., Okuda, K., & Shimada, M. (2021). New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine, 39(2), 197-201. https://doi.org/10.1016/j.vaccine.2020.11.054
Ura T, et al. New Vaccine Production Platforms Used in Developing SARS-CoV-2 Vaccine Candidates. Vaccine. 2021 01 8;39(2):197-201. PubMed PMID: 33279318.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. AU - Ura,Takehiro, AU - Yamashita,Akio, AU - Mizuki,Nobuhisa, AU - Okuda,Kenji, AU - Shimada,Masaru, Y1 - 2020/11/24/ PY - 2020/08/05/received PY - 2020/11/14/revised PY - 2020/11/17/accepted PY - 2020/12/7/pubmed PY - 2021/1/15/medline PY - 2020/12/6/entrez KW - SARS-CoV-2 KW - Vaccine KW - Vector SP - 197 EP - 201 JF - Vaccine JO - Vaccine VL - 39 IS - 2 N2 - The threat of the current coronavirus disease pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is accelerating the development of potential vaccines. Candidate vaccines have been generated using existing technologies that have been applied for developing vaccines against other infectious diseases. Two new types of platforms, mRNA- and viral vector-based vaccines, have been gaining attention owing to the rapid advancement in their methodologies. In clinical trials, setting appropriate immunological endpoints plays a key role in evaluating the efficacy and safety of candidate vaccines. Updated information about immunological features from individuals who have or have not been exposed to SARS-CoV-2 continues to guide effective vaccine development strategies. This review highlights key strategies for generating candidate SARS-CoV-2 vaccines and considerations for vaccine development and clinical trials. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/33279318/New_vaccine_production_platforms_used_in_developing_SARS_CoV_2_vaccine_candidates_ DB - PRIME DP - Unbound Medicine ER -